Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Horizon Therapeutics Public Limited Company    HZNP   IE00BQPVQZ61

HORIZON THERAPEUTICS PUBLIC LIMITED COMP

(HZNP)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/06/2019 12/09/2019 12/10/2019 12/11/2019 12/12/2019 Date
32.23(c) 31.89(c) 31.97(c) 32.25(c) 32.84(c) Last
760 892 990 294 1 161 407 1 660 891 1 706 366 Volume
+1.16% -1.05% +0.25% +0.88% +1.83% Change
More quotes
Financials (USD)
Sales 2019 1 286 M
EBIT 2019 469 M
Net income 2019 -56,9 M
Debt 2019 393 M
Yield 2019 -
Sales 2020 1 379 M
EBIT 2020 487 M
Net income 2020 63,2 M
Debt 2020 175 M
Yield 2020 -
P/E ratio 2019 -109x
P/E ratio 2020 99,5x
EV / Sales2019 5,09x
EV / Sales2020 4,59x
Capitalization 6 151 M
More Financials
Company
Horizon Therapeutics plc, formerly Horizon Pharma plc, is a rare disease biopharmaceutical company. The Company is focused on researching, developing and commercializing medicines that address needs for people impacted by rare and rheumatic diseases. The Company markets approximately 10 medicines,... 
Sector
Pharmaceuticals
Calendar
03/04Earnings Release
More about the company
Surperformance© ratings of Horizon Therapeutics Publi
Trading Rating : Investor Rating :
More Ratings
Latest news on HORIZON THERAPEUTICS PUBLI
12/13HORIZON THERAPEUTICS PUBLIC : FDA Advisory Committee Votes Unanimously to Suppor..
BU
12/13HORIZON THERAPEUTICS PLC : Trading Halted Today; FDA Dermatologic and Ophthalmic..
BU
12/09HORIZON THERAPEUTICS PLC : to Present at the 38th Annual J.P. Morgan Healthcare ..
BU
11/22HORIZON THERAPEUTICS PLC : Opens New Manufacturing and R&D Facility in South San..
BU
11/21HORIZON THERAPEUTICS PLC : Launches New Online Community Connecting People Livin..
BU
11/14HORIZON THERAPEUTICS PUBLIC : FORTUNE and Great Place to Work® Name Horizon Ther..
BU
11/13HORIZON THERAPEUTICS PLC : to Participate in Upcoming Investor Conferences
BU
11/11HORIZON THERAPEUTICS PUBLIC : Data from Uncontrolled Gout Case Series Supports I..
BU
11/08HORIZON THERAPEUTICS PUBLIC : The Chicago Tribune Names Horizon Therapeutics plc..
BU
11/06HORIZON THERAPEUTICS PLC : Reports Strong Third-Quarter 2019 Results
BU
11/05HORIZON THERAPEUTICS PLC : Brings Gout-Kidney Link into Focus during American So..
BU
11/04HORIZON THERAPEUTICS PUBLIC : Clinical Study Data Highlighting the Impact of Tep..
BU
11/04HORIZON THERAPEUTICS PUBLIC : New Evidence on the Burden of Gout to be Featured ..
BU
10/31HORIZON THERAPEUTICS PUBLIC : Integrated Clinical Trial Analyses Further Substan..
BU
10/24HORIZON THERAPEUTICS PLC : Named One of the Most Innovative Companies by Crain's..
BU
More news
News in other languages on HORIZON THERAPEUTICS PUBLI
2016Le laboratoire Depomed résigné à se vendre-sources
2016Les valeurs à suivre aujourd'hui à Wall Street - Lundi 12 septembre 2016
2016HORIZON PHARMA : acquiert Raptor Pharmaceutical
2015Les valeurs à suivre sur les marchés américains
2015WALL STREET STOCK EXCHANGE : Wall Street finit en baisse avec l'énergie et la di..
More news
Analyst Recommendations on HORIZON THERAPEUTICS PUBLI
More recommendations
Sector news : Pharmaceuticals - NEC
12/13EAGLE PHARMACEUTICALS : Pharma Shares up After It Says Settlement Reached With E..
DJ
12/13BRISTOL MYERS SQUIBB : Myers Executive VP Elicker to Retire; CVS's Metcalfe Taki..
DJ
12/13DAVIDSON KEMPNER CAPITAL MANAGEMENT : Form 8.3 - Allergan Plc
DJ
12/13ALLERGAN : Form 8.3 -
DJ
12/13ABBVIE : Form 8.3 -
DJ
More sector news : Pharmaceuticals - NEC
Chart HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
Duration : Period :
Horizon Therapeutics Public Limited Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HORIZON THERAPEUTICS PUBLI
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Average target price 35,64  $
Last Close Price 32,84  $
Spread / Highest target 18,8%
Spread / Average Target 8,52%
Spread / Lowest Target -2,56%
EPS Revisions
Managers
NameTitle
Timothy P. Walbert Chairman, President & Chief Executive Officer
Robert W. Metz Senior VP-Business Operations & Government Affairs
Paul W. Hoelscher Chief Financial Officer & Executive Vice President
Shao-Lee Lin Chief Scientific Officer
Michael A. DesJardin Executive Vice President-Technical Operations
Sector and Competitors
1st jan.Capitalization (M$)
HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY68.07%6 151
JOHNSON & JOHNSON9.24%371 989
ROCHE HOLDING AG24.22%261 794
MERCK AND COMPANY17.22%228 044
PFIZER-11.71%213 285
NOVARTIS22.85%209 621